Ibuzatrelvir

Antiviral drug

Ibuzatrelvir
[[File: Chemical structure of Ibuzatrelvir |frameless|220px|alt=|]]
INN
Drug class	Antiviral
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ibuzatrelvir is an antiviral drug that is used in the treatment of COVID-19. It is part of a class of medications known as protease inhibitors, which work by inhibiting the action of the SARS-CoV-2 main protease, an enzyme critical for the viral replication process.

Mechanism of Action

Ibuzatrelvir functions by targeting the 3C-like protease (3CL^pro) of the SARS-CoV-2 virus. This protease is essential for the cleavage of the viral polyprotein into functional units necessary for viral replication. By inhibiting this enzyme, Ibuzatrelvir effectively halts the replication of the virus within the host cells.

Pharmacokinetics

Ibuzatrelvir is administered orally and is rapidly absorbed into the bloodstream. It undergoes hepatic metabolism and is primarily excreted via the renal route. The drug has a half-life that allows for convenient dosing schedules, typically once or twice daily, depending on the severity of the infection and the patient's renal function.

Clinical Use

Ibuzatrelvir is indicated for the treatment of mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progression to severe disease, including hospitalization or death. It is most effective when administered early in the course of the infection.

Side Effects

Common side effects of Ibuzatrelvir include nausea, diarrhea, and headache. Some patients may experience liver enzyme elevations, and it is recommended to monitor liver function during treatment. Serious adverse effects are rare but can include allergic reactions and hepatic impairment.

Drug Interactions

Ibuzatrelvir can interact with other medications that are metabolized by the cytochrome P450 enzyme system, particularly CYP3A4. Caution is advised when co-administering with drugs such as anticoagulants, anticonvulsants, and certain antidepressants.

Development and Approval

Ibuzatrelvir was developed in response to the global COVID-19 pandemic as part of efforts to provide effective oral antiviral therapies. It received emergency use authorization from regulatory agencies based on clinical trial data demonstrating its efficacy in reducing viral load and preventing severe outcomes in high-risk patients.

Related Pages

• COVID-19 pandemic
• Antiviral drug
• Protease inhibitor
• SARS-CoV-2